Melanoma in Dogs: A Complete Guide for Dog Owners

Understanding Canine Melanoma: Types, Diagnosis, Treatment, and Prognosis by Location

---

When a dog is diagnosed with melanoma, the single most important question is not "what kind of melanoma?" but rather "where is it?" Location is the dominant factor in canine melanoma biology — a benign-looking skin lump on the trunk carries an entirely different prognosis than a mass in the mouth or at the nail bed. This distinction is fundamental to understanding what a melanoma diagnosis means for your dog.

Melanoma is one of the most commonly diagnosed cancers in dogs, arising from melanocytes — the pigment-producing cells derived from the neural crest during development. These cells are found throughout the body, which is why melanoma can appear virtually anywhere. But unlike human melanoma, canine melanoma is not caused by sun exposure or UV radiation. Instead, genetics, breed predisposition, and anatomic location drive both occurrence and behavior. In dogs, oral and subungual (nail bed) melanomas are the most common malignant forms; cutaneous melanomas on the skin of the trunk and limbs are frequently benign.

This guide explains what canine melanoma is, how it behaves differently depending on where it arises, how it is diagnosed and staged, what treatments are available, and what outcomes families can realistically expect.

What Is Melanoma?

Melanoma is a neoplasm — an abnormal, uncontrolled proliferation — of melanocytes. In dogs, these tumors can be benign (melanocytomas) or malignant, and that distinction is not always apparent from appearance alone. A dark, heavily pigmented lump may be completely benign. A pale, unpigmented (amelanotic) mass may be highly aggressive. Pigmentation is not a reliable indicator of malignant potential in dogs.

Malignant melanoma in dogs behaves aggressively: it invades local tissues, can destroy underlying bone, and carries a high propensity for metastasis — particularly to the regional lymph nodes and lungs. Unlike the UV-driven mutations seen in most human melanoma subtypes, canine melanoma is driven by genetic factors, with specific breeds demonstrating strikingly elevated risk for particular subtypes.

Key Distinction from Human Melanoma: In humans, sun exposure on the skin is the major cause of melanoma, and cutaneous (skin) melanomas are the most common and most aggressive form. In dogs, the opposite is true — cutaneous melanomas on haired skin are usually benign, while oral and nail-bed melanomas are the most common malignant types. This is one of the important biological differences between the two species.

Types of Canine Melanoma by Location

Location is the single most important determinant of a canine melanoma's behavior. The same tumor type behaves very differently depending on where it arises.

Oral Melanoma

Oral melanoma is the most common malignant melanoma in dogs and one of the most common oral tumors in the species overall. It most frequently arises on the gingiva (gums), but can also develop on the lips, tongue, palate, tonsils, and oropharynx. Mean age at diagnosis is approximately 10 to 11 years, and several breeds are strongly predisposed.

Oral melanoma is highly aggressive. It invades local tissues rapidly — often destroying underlying bone — and has a high metastatic rate to regional lymph nodes and lungs. At the time of diagnosis, a significant proportion of dogs already have regional or distant metastatic disease. Median survival time without treatment is poor, and even with multimodal therapy, most dogs will ultimately succumb to metastatic disease. Oral melanoma is the most important and most studied form of malignant melanoma in veterinary oncology.

Subungual (Nail Bed) and Digital Melanoma

Subungual melanoma arises at or beneath the nail bed, where the skin meets the claw. It is highly malignant — the 2024 Frontiers consensus guidelines note that 19 to 30 percent of dogs with subungual melanoma have regional lymph node metastasis at the time of diagnosis. These tumors frequently invade the underlying bone of the toe (the third phalanx), and digital amputation is often required.

The presenting signs are easily mistaken for nail infections or trauma: swelling around the toe, lameness, a loose or bleeding nail, or a mass near the claw. Because of this, subungual melanoma is frequently misdiagnosed early, and delays in diagnosis are common. Any persistent toe swelling or nail abnormality in a middle-aged to older dog warrants prompt veterinary evaluation and imaging.

Cutaneous (Skin) Melanoma

Cutaneous melanoma on the haired skin of the trunk, limbs, or face behaves very differently from oral or subungual forms. The majority of cutaneous melanomas in dogs are benign melanocytomas. They typically appear as firm, dark, raised masses that grow slowly and do not spread. Complete surgical removal is usually curative.

However, a subset of cutaneous melanomas — particularly those on the digits, footpads, lips, or scrotum — carry higher malignant potential. Histopathological evaluation is essential, because visual appearance is unreliable. Even a tumor that appears benign may behave malignantly based on its microscopic features.

Ocular Melanoma

Melanoma can arise from the uveal structures of the eye (iris, ciliary body, choroid) or the eyelid and conjunctiva. Uveal melanoma is locally aggressive but tends to have limited metastatic potential compared to oral melanoma. Eyelid melanoma behavior is more variable. Treatment may involve surgical debulking, laser ablation, or in advanced cases, enucleation (eye removal) to prevent spread and control pain.

Critical Point: Do not assume a melanoma is benign because it is on the skin. Location matters enormously, but histopathology — microscopic evaluation of the tumor cells — is the only reliable way to determine malignant potential. Any new mass your dog develops, especially one that is growing, should be evaluated and sampled by a veterinarian.

Which Dogs Are Most at Risk?

Breed Predispositions

Canine melanoma has well-documented breed predispositions, and specific breeds tend toward specific subtypes:

• Miniature and Standard Poodle — among the highest risk for oral melanoma; more than 85 percent of melanocytic neoplasms in Miniature Poodles are malignant in some studies
• Scottish Terrier — strong predisposition to cutaneous and oral melanoma
• Miniature Schnauzer — predisposed, though more than 75 percent of melanocytic tumors in Schnauzers behave benignly
• Doberman Pinscher — predisposed; similarly, more than 75 percent of melanocytic neoplasms exhibit benign behavior
• Chow Chow — elevated risk for oral melanoma
• Golden Retriever — frequently represented in oral melanoma case series
• Labrador Retriever — elevated oral melanoma risk
• Cocker Spaniel — elevated oral melanoma risk; Golden Retrievers, Labrador Retrievers, and Cocker Spaniels collectively represent approximately one-third of dogs in multiple oral melanoma studies
• Rottweiler — elevated oral melanoma risk
• Yorkshire Terrier — elevated oral melanoma risk

Age and Sex

Oral melanoma tends to affect older dogs, with a mean age at diagnosis of approximately 10 to 11 years. Subungual and digital melanoma also predominantly affect older animals. Sex predisposition has been a subject of historical debate — earlier reports suggested male dogs were more frequently affected, but more recent studies have not demonstrated significant sex differences in survival or frequency.

Recognizing the Signs

Oral Melanoma Signs

• A mass on the gum, lip, tongue, or palate — may be pigmented (dark brown or black) or entirely unpigmented (amelanotic, pink or red)
• Facial swelling, particularly around the jaw
• Difficulty eating, chewing, or swallowing
• Drooling, sometimes blood-tinged
• Bad breath (halitosis) — often more severe than typical dental odor
• Loose teeth in the area of the tumor
• Visible asymmetry of the face or jaw
• Weight loss from difficulty eating

Subungual and Digital Melanoma Signs

• Swollen, painful toe — often mistaken for infection or injury
• Lameness on the affected foot
• A loose, bleeding, or misshapen nail
• A visible mass near the claw
• Licking or chewing at the affected toe
• Bone destruction on radiographs (X-rays) of the digit

Cutaneous Melanoma Signs

• A firm, raised skin mass — often dark but may be pink or flesh-colored
• Slow growth over months to years (benign) or rapid growth with ulceration (malignant)
• Masses around the lips, eyelids, scrotum, or digits warrant higher suspicion for malignancy
• Ulceration or bleeding from the surface

Warning: Do not wait to see if an oral mass resolves. Oral melanoma is aggressive, locally invasive, and highly metastatic. Most dogs diagnosed with oral melanoma already have regional lymph node involvement at the time of diagnosis. Early evaluation is critical.

Diagnosis

Physical Examination and Cytology

Initial evaluation involves a thorough physical examination with careful assessment of the oral cavity, regional lymph nodes, and any identified masses. Fine needle aspirate (FNA) cytology of the primary mass and regional lymph nodes provides rapid, minimally invasive information. For pigmented melanomas, cytology is often highly diagnostic — darkly pigmented cells are characteristic. However, amelanotic melanomas (lacking visible melanin) can be diagnostically challenging and may resemble other tumor types on cytology alone.

Biopsy and Histopathology

Definitive diagnosis requires histopathological examination of a tissue biopsy. For oral tumors, this should be obtained by biopsy through the mucosa rather than through the skin, to avoid tumor seeding. Deep wedge or core punch biopsies are preferable for oral masses, as superficial scraping samples from ulcerated or necrotic surfaces often miss the diagnostic tissue.

Histopathological evaluation provides not only a diagnosis but also critical prognostic information: mitotic rate, nuclear atypia, degree of pigmentation, Ki-67 proliferation index, presence of vascular invasion, and tumor thickness. These features collectively determine the histological grade, which is one of the most important prognostic indicators.

For amelanotic melanomas — which lack visible melanin pigmentation and can closely resemble soft tissue sarcomas — immunohistochemical (IHC) staining is essential. The standard diagnostic cocktail includes antibodies against Melan-A, PNL-2, TRP-1 (tyrosinase-related protein 1), and TRP-2. For challenging cases, RNA expression analysis for TYR, CD34, and CALD can further differentiate melanoma from sarcoma.

Staging

Thorough staging is essential for treatment planning and prognosis:

• Oral melanoma: Uses the WHO clinical staging scheme:
  • Stage I: tumor less than 2 cm diameter, no metastasis
  • Stage II: tumor 2 to 4 cm diameter, no metastasis
  • Stage III: tumor greater than 4 cm and/or regional lymph node metastasis
  • Stage IV: distant metastasis
• Other locations: TNM-based staging applies
• Thoracic radiographs (3 views) or thoracic CT — pulmonary metastasis screening; CT is more sensitive for small nodules
• Regional lymph node aspirate — ipsilateral and contralateral nodes for oral melanoma, given variability in lymphatic drainage patterns
• CT of the head — optimal for surgical planning of jaw-invasive oral melanoma; provides superior assessment of bone involvement
• Complete blood count and biochemical profile — baseline assessment
• Abdominal ultrasound — assessment for abdominal metastasis

Staging Note: For oral melanoma, both ipsilateral and contralateral mandibular lymph nodes should be aspirated, as the lymphatic drainage pattern is variable and metastasis does not always follow predictable anatomic pathways. CT imaging provides far better delineation of bone invasion than radiography and is strongly preferred for surgical planning.

Treatment Options

Treatment strategy depends on tumor location, clinical stage, and patient health status. The goals of treatment are local tumor control and systemic disease management.

Surgery

Surgical resection with wide margins is the cornerstone of treatment for all forms of canine melanoma. For oral melanoma, this typically means aggressive jaw surgery — mandibulectomy (partial removal of the lower jaw) or maxillectomy (partial removal of the upper jaw). Wide resection that includes a 2 to 3 cm bone margin and at least 1 cm of soft tissue margin achieves complete excision in approximately 72 to 79 percent of cases in reported series, with local recurrence rates of approximately 8 to 10 percent in completely excised cases.

Dogs tolerate jaw surgeries — even aggressive ones — remarkably well. They adapt to altered jaw anatomy with impressive resilience, and most owners report good quality of life following recovery. For digital melanoma, amputation of the affected toe is standard and typically provides good local control.

Excision of regional lymph nodes is recommended for oral, subungual, footpad, and cutaneous melanoma. Lymph node assessment adds important staging information, though the therapeutic benefit of lymph node dissection beyond its diagnostic value has not been definitively established.

Radiation Therapy

Radiation therapy is an integral component of managing oral melanoma, both as a primary treatment when surgery is not feasible and as adjuvant therapy when margins are incomplete or when regional disease control is a concern. Coarse fractionation protocols (typically 4 to 6 treatments given weekly) are most commonly used and are well-tolerated.

Melanoma is historically considered "radioresistant" when treated with small doses per fraction. However, coarse fractionation — larger doses per fraction — has demonstrated meaningful response rates for canine oral melanoma, with clinical responses reported in a substantial proportion of treated dogs. The median survival for dogs with oral melanoma treated with radiation alone (without surgery) using these protocols is approximately 5 to 7 months. When used as adjuvant therapy following surgery, it contributes to local disease control. Radiation therapy also appears to increase antigen expression on tumor cells, potentially enhancing the efficacy of subsequent immunotherapy.

The Oncept Vaccine (Immunotherapy)

The most significant advancement in canine melanoma treatment is the ONCEPT Canine Melanoma Vaccine — a xenogeneic DNA vaccine that is USDA-approved for treatment of stage II and stage III canine oral melanoma with adequate local disease control. It is the first cancer vaccine licensed for use in any species.

ONCEPT contains plasmid DNA encoding human tyrosinase — an enzyme involved in melanin synthesis that is highly conserved between dogs and humans but sufficiently different to be recognized as foreign by the canine immune system. When injected, it stimulates an immune response against tyrosinase-expressing tumor cells. The protocol involves four biweekly injections followed by booster doses every 6 months.

A landmark multicenter trial demonstrated significantly improved survival times in vaccinated dogs compared to historical controls (p < 0.0001). Multiple real-world studies have since reported median survival times of 335 to 510 days in dogs with oral melanoma treated with Oncept as part of multimodal therapy, compared to median survivals of approximately 5 to 6 months with surgery alone at Stage II/III.

The vaccine is generally well-tolerated, with minimal side effects — mild local reaction at the injection site being the most commonly reported. Importantly, the 2024 Frontiers consensus guidelines note that the vaccine appears most effective when macroscopic disease has been controlled by surgery and/or radiation, functioning optimally to address microscopic residual disease. Its role in treating gross disease is more limited, though clinical responses have been observed in some dogs with macroscopic disease.

It should be noted that the published data on Oncept is mixed regarding the magnitude of survival benefit, and the vaccine is considered somewhat controversial in some veterinary oncology circles. Despite this, it remains the standard of care for eligible patients and is widely used.

A newer development as of 2024 is Gilvetmab — a caninized anti-PD-1 monoclonal antibody, representing the first checkpoint inhibitor to receive conditional licensure in the United States for canine melanoma. In an initial study of 25 dogs with stage 2 or 3 melanoma, complete response was noted in 2 dogs, partial response in 3, and stable disease in 10 — early data suggesting potential clinical utility, with further study ongoing.

Chemotherapy

Systemic chemotherapy has shown modest activity against canine melanoma. Carboplatin, dacarbazine, and melphalan have been used with varying degrees of response. Chemotherapy is generally offered to dogs with advanced, metastatic, or incompletely controlled disease. Unlike osteosarcoma — where adjuvant chemotherapy substantially extends survival — chemotherapy does not play the same central role in melanoma management. It may be considered as adjuvant therapy in high-risk cases or for palliative management of metastatic disease.

Electrochemotherapy

Electrochemotherapy — the combination of electrically induced cell membrane permeability with low-dose chemotherapy (typically bleomycin or cisplatin) — has demonstrated responses in canine melanoma, particularly for accessible cutaneous or accessible oral masses. It is used in some European veterinary oncology centers and represents an option when surgery is not feasible or for palliative control of accessible masses.

Prognosis: Understanding Survival Data by Location

Location is the dominant prognostic variable in canine melanoma. The table below summarizes median survival data:

These are population-level estimates; individual outcomes vary significantly based on stage, histopathological features, completeness of resection, and access to multimodal therapy.

Histopathological Prognostic Factors

In addition to location, the following microscopic features carry strong prognostic significance and are assessed in every melanoma biopsy evaluation:

• Mitotic count — the most consistently validated histological prognostic marker; higher mitotic rate correlates strongly with malignant behavior and shorter survival
• Nuclear atypia — a threshold of greater than 30 percent of cells with atypical nuclei (from a count of 200 cells) is associated with poor prognosis for oral and lip tumors; greater than 20 percent for cutaneous tumors
• Ki-67 proliferation index — higher Ki-67 indicates more actively dividing cells and correlates with worse prognosis
• Tumor thickness — greater thickness associated with more aggressive behavior
• Vascular invasion — presence indicates higher metastatic risk
• Degree of pigmentation — variable significance; amelanotic melanomas can be more difficult to classify but do not universally carry worse prognosis
• Tumor-infiltrating lymphocytes — emerging evidence suggests that greater density of tumor-infiltrating lymphocytes correlates with better therapeutic response and outcomes

Negative Prognostic Factors (Clinical)

• Oral or subungual location
• Stage III or IV disease
• Tumor diameter greater than 2 cm (for oral melanoma)
• Regional lymph node involvement
• Detectable pulmonary or distant metastasis at diagnosis
• Incomplete surgical excision
• High mitotic rate or Ki-67 index on histopathology
• Vascular invasion on histopathology

Emerging and Investigational Treatments

Checkpoint Inhibitors

Checkpoint inhibitors — antibodies that block inhibitory signals that tumors use to suppress the immune system — have transformed human melanoma treatment. Gilvetmab, the first caninized anti-PD-1 checkpoint inhibitor for dogs, received conditional licensure in the United States in 2024. It represents a significant new option and is expected to be studied further in combination with Oncept and other therapies. Additional checkpoint inhibitors targeting the PD-1/PD-L1 and CTLA-4 pathways are in development for canine patients.

CSPG4-Targeted DNA Vaccines

Chondroitin sulfate proteoglycan 4 (CSPG4), also known as high molecular weight melanoma-associated antigen, is a cell-surface marker expressed in canine melanoma that is associated with proliferation, migration, and invasion. It appears to be expressed more frequently in amelanotic melanomas. A DNA vaccine targeting CSPG4 is under development and represents a complementary immunotherapy approach to Oncept.

Targeted Molecular Therapies

Unlike human UV-induced melanoma — which frequently harbors BRAF mutations amenable to targeted inhibition — canine melanoma has different molecular drivers. NRAS, PTEN, KIT, and ERK1/2 alterations have been described. Research into molecular targeted therapies specific to canine melanoma biology, including KIT inhibitors and MEK/ERK pathway inhibitors, is ongoing. The KIT inhibitor masitinib has shown mild activity in stage 3 and 4 disease.

Clinical Trials: Oral melanoma is one of the most actively studied cancers in veterinary comparative oncology. If your dog has received an oral melanoma diagnosis, asking for a referral to a veterinary oncologist about clinical trial availability is strongly worthwhile. Canine melanoma models are directly informing the development of treatments for rare human melanoma subtypes, including oral and acral melanoma.

Integrative and Supportive Care

Oral Health and Comfort

For dogs with oral melanoma managed surgically, post-operative oral care is important. Soft foods, avoidance of hard chews or toys, and gentle oral hygiene support healing. Many dogs adapt remarkably quickly to altered jaw anatomy after mandibulectomy or maxillectomy — most owners are pleasantly surprised by how well their dogs eat and maintain weight after these surgeries.

Nutrition

A high-quality diet with adequate protein supports healing and immune function. For dogs undergoing radiation therapy to the oral cavity, transient mucositis (inflammation of oral tissues) may make eating painful during treatment — softer food consistency and, in some cases, appetite stimulants or feeding tubes may be needed for a period. Fish oil supplementation (EPA and DHA omega-3 fatty acids) has anti-inflammatory properties and is generally well-tolerated.

Pain Management

Oral melanoma and digital melanoma can cause significant pain through tissue invasion, bone destruction, and treatment side effects. Adequate multimodal pain management is essential:

• NSAIDs — carprofen, meloxicam, or deracoxib for baseline inflammation and pain
• Gabapentin — neuropathic pain, particularly relevant for bone-invasive tumors
• Tramadol or other opioids — for moderate to severe pain
• Local wound care — for digital lesions and post-operative oral sites

Immune Support

Nutritional and nutraceutical approaches to supporting immune function are often incorporated into integrative cancer care. Medicinal mushrooms (turkey tail, reishi, maitake), omega-3 fatty acids, and antioxidant supplementation are commonly discussed — discuss all supplements with your veterinary oncologist, as some may interfere with immunotherapy or chemotherapy.

Monitoring and Recurrence

Dogs treated for malignant melanoma require structured follow-up monitoring to detect recurrence or metastasis early:

• Oral re-examination every 4 to 8 weeks for the first year
• Thoracic radiographs or CT every 2 to 3 months for pulmonary metastasis surveillance
• Regional lymph node assessment at each visit
• Complete physical examination including abdominal palpation

Local recurrence and development of distant metastasis are the most common causes of treatment failure. Early detection of recurrence allows for faster intervention and may extend quality time.

Frequently Asked Questions

I found a dark lump in my dog's mouth. Is it definitely melanoma?

Not necessarily — not all dark oral masses are melanoma, and not all oral melanomas are dark. Oral masses in dogs can be squamous cell carcinoma, fibrosarcoma, peripheral odontogenic fibroma, lymphoma, or benign reactive tissue proliferations. Any oral mass requires biopsy for definitive diagnosis. However, a dark, fast-growing, ulcerated oral mass in a middle-aged or older dog of a predisposed breed is suspicious enough that prompt veterinary evaluation and staging is warranted.

What does "amelanotic" mean, and does it affect prognosis?

Amelanotic means the tumor cells are not producing visible melanin pigment, so the mass appears pink, red, or flesh-colored rather than dark. Amelanotic melanomas are diagnostically challenging because they can look identical to other tumor types visually and on cytology. Immunohistochemical staining (IHC) is required for diagnosis. Amelanotic tumors do not inherently carry a worse prognosis than pigmented ones — prognosis is determined more by location, stage, and histopathological features than by pigmentation.

My dog has a swollen, sore toe. Could it be melanoma?

Subungual (nail bed) melanoma is one of the most commonly misdiagnosed canine tumors because its signs — swelling, pain, lameness, nail changes — mimic infection and trauma. Any toe swelling in an older dog that does not resolve with appropriate antibiotic treatment, or that recurs, or that shows bone involvement on X-ray, should be biopsied. Melanoma accounts for approximately 15 to 17 percent of all canine digital tumors.

What is the Oncept vaccine and how does it work?

Oncept is a xenogeneic (cross-species) DNA vaccine that uses human tyrosinase gene sequences to stimulate the dog's immune system to recognize and attack tyrosinase-expressing melanoma cells. It is delivered by intramuscular injection, typically four doses given every two weeks, with boosters every six months. It is USDA-approved for stage II and III oral melanoma with adequate local disease control. The vaccine is generally well-tolerated and has shown improved survival in clinical and real-world studies, though results across the literature are variable and its use is considered standard but not without ongoing debate regarding magnitude of benefit.

Is jaw surgery as serious as it sounds?

Dogs tolerate mandibulectomy (lower jaw removal, partial) and maxillectomy (upper jaw removal, partial) remarkably well. They adapt to altered jaw anatomy with a speed and resilience that consistently surprises owners. Studies of quality of life after jaw surgeries in dogs show that the majority of patients eat, drink, play, and engage in normal activities within weeks of surgery. The cosmetic result — while different — is something most owners and dogs adapt to with time. The relief from the pain of a bone-invasive tumor is often immediate and dramatic.

Can a benign melanocytoma turn malignant?

This is not well-established in dogs. More commonly, what appears to be a "benign" mass based on visual appearance turns out on histopathology to have malignant features — emphasizing why every excised melanocytic tumor, regardless of appearance, should be submitted for histopathological evaluation. Any melanocytic tumor that is rapidly growing, ulcerating, or at a high-risk location (digits, footpads, scrotum, lips) should be prioritized for prompt evaluation.

What should I do if I find an unusual skin lump on my dog?

Document it with a photograph and take your dog to a veterinarian promptly. Note when you first noticed it, how quickly it seems to be growing, whether it has changed in color or surface texture, and whether your dog seems bothered by it. Do not watch and wait beyond a few weeks for any new mass, particularly in older dogs or predisposed breeds. Early surgical removal of melanocytic tumors, before they have metastasized, offers the best outcomes.

Is melanoma treatable in dogs?

For cutaneous melanoma on the haired skin: yes, very well — most are benign and surgical removal is curative. For oral and subungual melanoma: treatment significantly extends survival and quality of life, but most dogs will ultimately develop systemic metastasis. The goal of treatment is to provide the longest possible period of good-quality, comfortable life. With multimodal therapy including surgery, radiation, and Oncept, a meaningful subset of dogs with oral melanoma achieve survival times well beyond 12 months.

When should euthanasia be considered?

Quality-of-life assessment tools — such as the HHHHHMM Scale developed by Dr. Alice Villalobos — provide a structured framework for evaluating pain, appetite, hydration, hygiene, happiness, mobility, and overall quality of life.

For dogs with melanoma, the most common end-stage concerns are uncontrolled oral pain or inability to eat from local disease recurrence; respiratory compromise from pulmonary metastasis; or severe lameness from metastatic bone involvement. 

When pain cannot be adequately managed, when eating has become too difficult to maintain adequate nutrition, or when your dog's enjoyment of daily life has substantially diminished, an honest conversation with your veterinarian about humane euthanasia is appropriate and compassionate.

References

1. Polton G, Borrego JF, Clemente-Vicario F, Clifford CA, Jagielski D, Kessler M, Kobayashi T, Lanore D, Queiroga FL, Rowe AT, Vajdovich P, Bergman PJ. Melanoma of the dog and cat: consensus and guidelines. Frontiers in Veterinary Science, 11:1359426, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11026649/
2. Stevenson VB, Klahn S, LeRoith T, Huckle WR. Canine melanoma: a review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies. Frontiers in Veterinary Science, 9:1046636, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC9853198/
3. Smedley RC, Bongiovanni L, Bacmeister C, et al. Diagnosis and histopathologic prognostication of canine melanocytic neoplasms: a consensus of the Oncology-Pathology Working Group. Veterinary Pathology, 58(3):394–411, 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC9796073/
4. Prouteau A, André C. Canine melanomas as models for human melanomas: clinical, histological, and genetic comparison. Genes, 10(7):501, 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6678806/
5. Fonseca-Alves CE, Ferreira E, de Oliveira Massoco C, et al. Current status of canine melanoma diagnosis and therapy: report from a colloquium on canine melanoma organized by ABROVET. Frontiers in Veterinary Science, 8:707235, 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8415562/
6. Fard SS, Müller J, Hahn A, Nolte I, Murua Escobar H. The comparative oncology of canine malignant melanoma in targeted therapy: a systematic review of in vitro experiments and animal model reports. International Journal of Molecular Sciences, 25(19):10387, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11476434/
7. Bergman PJ. Canine oral melanoma. Clinical Techniques in Small Animal Practice, 22(2):55–60, 2007. https://www.sciencedirect.com/science/article/abs/pii/S1096286707000126
8. Smedley RC, Spangler WL, Esplin DG, et al. Prognostic markers for canine melanocytic neoplasms. Veterinary Pathology, 48(1):88–101, 2011. https://journals.sagepub.com/doi/10.1177/0300985810390717
9. Grosenbaugh DA, Leard AT, Bergman PJ, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding an orthologue of the human tyrosinase gene in canine malignant melanoma. Vaccine, 29(26):4582–4589, 2011. https://pubmed.ncbi.nlm.nih.gov/21871581/
10. Verganti S, Berlato D, Blackwood L, et al. Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK. Journal of Small Animal Practice, 58(1):10–16, 2017. https://pubmed.ncbi.nlm.nih.gov/28094857/
11. McLean JL, Lobetti RG. Use of the melanoma vaccine in 69 dogs with malignant melanoma. Journal of the South African Veterinary Association, 86(1):1244, 2015. https://pubmed.ncbi.nlm.nih.gov/32323424/
12. Treggiari E, Grant JP, North SM. A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma. Journal of Veterinary Medical Science, 78(5):845–850, 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC4905841/
13. Tuohy JL, Selmic LE, Worley DR, Ehrhart NP, Withrow SJ. Outcome following curative-intent surgery for oral melanoma in dogs: 70 cases (1998–2011). Journal of the American Veterinary Medical Association, 245(11):1266–1273, 2014. https://pubmed.ncbi.nlm.nih.gov/25380199/
14. Marcinowska A, Warland J, Brearley M, et al. Multimodality treatment including ONCEPT for canine oral melanoma: a retrospective analysis of 131 dogs. Veterinary and Comparative Oncology, 18(3):335–344, 2020. https://pubmed.ncbi.nlm.nih.gov/32323424/
15. Boston SE, Lu X, Culp WT, et al. Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001–2012). Journal of the American Veterinary Medical Association, 245(4):401–407, 2014. https://pubmed.ncbi.nlm.nih.gov/25075831/
16. Blackwood L, Murphy S, Buracco P, et al. European consensus document on mast cell tumours in dogs and cats. Veterinary and Comparative Oncology, 10(3):e1–e29, 2012. https://pubmed.ncbi.nlm.nih.gov/22151203/
17. Proulx DR, Ruslander DM, Dodge RK, et al. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Veterinary Radiology and Ultrasound, 44(3):352–359, 2003. https://pubmed.ncbi.nlm.nih.gov/12816389/
18. Manley CA, Leibman NF, Wolchok JD, et al. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. Journal of Veterinary Internal Medicine, 25(1):94–99, 2011. https://pubmed.ncbi.nlm.nih.gov/21143662/
19. Cornell Richard P. Riney Canine Health Center. Oral melanoma in dogs. Cornell University College of Veterinary Medicine, 2023. https://www.vet.cornell.edu/departments-centers-and-institutes/riney-canine-health-center/canine-health-topics/oral-tumors
20. Mauldin EA, Peters-Kennedy J. Integumentary system. In Maxie MG (ed.), Jubb, Kennedy and Palmer's Pathology of Domestic Animals, 6th ed. Elsevier, 2016. https://www.sciencedirect.com/book/9780702052775/jubb-kennedy-and-palmers-pathology-of-domestic-animals

---

This article is intended for educational purposes only and does not constitute veterinary medical advice. Always consult a licensed veterinarian or board-certified veterinary oncologist for guidance specific to your dog's health needs.